oteseconazole是一种口服给药的真菌CYP51抑制剂，在一年内使90%的女性免于复发。 复发性外阴阴道念珠菌病（RVVC，图片来源：cliniexpert.com） 2021年07月28 ...

A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast ...

and Oteseconazole, used to treat fungal infections in females. G 2 Retro was able to correctly generate exactly the same patented synthesis routes for these medicines, and provided alternative ...

Credit: Getty Images. Oteseconazole is a novel oral inhibitor of fungal CYP51. Topline results were announced from two phase 3 trials evaluating oteseconazole (VT-1161; Mycovia Pharmaceuticals ...

DURHAM, N.C.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved VIVJOA™ (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent ...

About VIVJOA™ VIVJOA™ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are ...

DURHAM – Mycovia Pharmaceuticals has submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for oteseconazole, an oral antifungal product for the ...

("Mycovia"), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today shared topline results from ...